• Users Online: 832
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2020  |  Volume : 11  |  Issue : 2  |  Page : 65-70

The role of hydroxychloroquine in COVID-19: Where do we stand?


1 Department of Diabetology, Dr. Mohan’s Diabetes Specialities Centre, Chennai, Tamil Nadu, India; Department of Diabetology, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India
2 Department of Diabetology, Dr. Mohan’s Diabetes Specialities Centre, Chennai, Tamil Nadu, India

Correspondence Address:
Dr. Ranjit Mohan Anjana
Department of Diabetology, Madras Diabetes Research Foundation and Department of Diabetology, Dr. Mohan’s Diabetes Specialities Centre, 4, Conran Smith Road, Gopalapuram, Chennai 600086, Tamil Nadu.
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JOD.JOD_33_20

Rights and Permissions

Hydroxychloroquine (HCQ) is a drug, which has long been used in the treatment of malaria, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren’s syndrome. Recently with the COVID-19 pandemic hitting the world, there have been studies suggesting that hydroxychloroquine may be useful both in the prevention and the treatment of COVID-19, although the evidence so far has been conflicting. This article reviews the available evidence for the use of hydroxychloroquine in COVID-19 and also mentions some of the ongoing trials in this field.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed539    
    Printed32    
    Emailed0    
    PDF Downloaded136    
    Comments [Add]    

Recommend this journal